^
    Back
    Association details:
    Biomarker:SRC T341I
    Cancer:Cholangiocarcinoma
    Drug:dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: D – Preclinical
    New
    Source:
    Cancer Discov
    Title:

    Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma

    Excerpt:
    In addition, whereas dasatinib fully inhibited SRC activity in the parental cells, as evidenced by loss of Y416 phosphorylation, the SRCT341I cells were resistant…
    DOI:
    10.1158/2159-8290.CD-15-1442